Skip to main content
. 2022 Mar 17;64:151–158. doi: 10.1016/j.breast.2022.03.001

Fig. 3.

Fig. 3

Final analysis of OS of SafeHER for the (A) entire ITT population, (B) no chemotherapy subgroup, (C) concurrent chemotherapy subgroup, and (D) sequential chemotherapy subgroup. ITT, intent-to-treat; OS, overall survival.